245 related articles for article (PubMed ID: 38252832)
41. Targeting microbubbles-carrying TGFβ1 inhibitor combined with ultrasound sonication induce BBB/BTB disruption to enhance nanomedicine treatment for brain tumors.
Chen YC; Chiang CF; Wu SK; Chen LF; Hsieh WY; Lin WL
J Control Release; 2015 Aug; 211():53-62. PubMed ID: 26047759
[TBL] [Abstract][Full Text] [Related]
42. Reactive oxidative species (ROS)-based nanomedicine for BBB crossing and glioma treatment: current status and future directions.
Wu D; Chen X; Zhou S; Li B
Front Immunol; 2023; 14():1241791. PubMed ID: 37731484
[TBL] [Abstract][Full Text] [Related]
43. The proton permeability of self-assembled polymersomes and their neuroprotection by enhancing a neuroprotective peptide across the blood-brain barrier after modification with lactoferrin.
Yu Y; Jiang X; Gong S; Feng L; Zhong Y; Pang Z
Nanoscale; 2014 Mar; 6(6):3250-8. PubMed ID: 24503971
[TBL] [Abstract][Full Text] [Related]
44. Glycaemic control boosts glucosylated nanocarrier crossing the BBB into the brain.
Anraku Y; Kuwahara H; Fukusato Y; Mizoguchi A; Ishii T; Nitta K; Matsumoto Y; Toh K; Miyata K; Uchida S; Nishina K; Osada K; Itaka K; Nishiyama N; Mizusawa H; Yamasoba T; Yokota T; Kataoka K
Nat Commun; 2017 Oct; 8(1):1001. PubMed ID: 29042554
[TBL] [Abstract][Full Text] [Related]
45. Nanoscale drug delivery systems and the blood-brain barrier.
Alyautdin R; Khalin I; Nafeeza MI; Haron MH; Kuznetsov D
Int J Nanomedicine; 2014; 9():795-811. PubMed ID: 24550672
[TBL] [Abstract][Full Text] [Related]
46. Smart Nanomedicine to Enable Crossing Blood-Brain Barrier Delivery of Checkpoint Blockade Antibody for Immunotherapy of Glioma.
Wang H; Chao Y; Zhao H; Zhou X; Zhang F; Zhang Z; Li Z; Pan J; Wang J; Chen Q; Liu Z
ACS Nano; 2022 Jan; 16(1):664-674. PubMed ID: 34978418
[TBL] [Abstract][Full Text] [Related]
47. A nanomedicine transports a peptide caspase-3 inhibitor across the blood-brain barrier and provides neuroprotection.
Karatas H; Aktas Y; Gursoy-Ozdemir Y; Bodur E; Yemisci M; Caban S; Vural A; Pinarbasli O; Capan Y; Fernandez-Megia E; Novoa-Carballal R; Riguera R; Andrieux K; Couvreur P; Dalkara T
J Neurosci; 2009 Nov; 29(44):13761-9. PubMed ID: 19889988
[TBL] [Abstract][Full Text] [Related]
48. Theranostic quantum dots for crossing blood-brain barrier in vitro and providing therapy of HIV-associated encephalopathy.
Xu G; Mahajan S; Roy I; Yong KT
Front Pharmacol; 2013 Nov; 4():140. PubMed ID: 24298256
[TBL] [Abstract][Full Text] [Related]
49. An overview of in vitro 3D models of the blood-brain barrier as a tool to predict the in vivo permeability of nanomedicines.
Pérez-López A; Torres-Suárez AI; Martín-Sabroso C; Aparicio-Blanco J
Adv Drug Deliv Rev; 2023 May; 196():114816. PubMed ID: 37003488
[TBL] [Abstract][Full Text] [Related]
50. Ultrasound-mediated blood-brain barrier opening: An effective drug delivery system for theranostics of brain diseases.
Wang J; Li Z; Pan M; Fiaz M; Hao Y; Yan Y; Sun L; Yan F
Adv Drug Deliv Rev; 2022 Nov; 190():114539. PubMed ID: 36116720
[TBL] [Abstract][Full Text] [Related]
51. Micro-Nanocarriers Based Drug Delivery Technology for Blood-Brain Barrier Crossing and Brain Tumor Targeting Therapy.
Wang L; Shi Y; Jiang J; Li C; Zhang H; Zhang X; Jiang T; Wang L; Wang Y; Feng L
Small; 2022 Nov; 18(45):e2203678. PubMed ID: 36103614
[TBL] [Abstract][Full Text] [Related]
52. High-resolution Confocal Imaging of the Blood-brain Barrier: Imaging, 3D Reconstruction, and Quantification of Transcytosis.
Villaseñor R; Collin L
J Vis Exp; 2017 Nov; (129):. PubMed ID: 29286366
[TBL] [Abstract][Full Text] [Related]
53. Imaging and nanomedicine for diagnosis and therapy in the central nervous system: report of the eleventh annual Blood-Brain Barrier Disruption Consortium meeting.
Muldoon LL; Tratnyek PG; Jacobs PM; Doolittle ND; Christoforidis GA; Frank JA; Lindau M; Lockman PR; Manninger SP; Qiang Y; Spence AM; Stupp SI; Zhang M; Neuwelt EA
AJNR Am J Neuroradiol; 2006 Mar; 27(3):715-21. PubMed ID: 16552023
[TBL] [Abstract][Full Text] [Related]
54. Mucus barrier-triggered disassembly of siRNA nanocarriers.
Thomsen TB; Li L; Howard KA
Nanoscale; 2014 Nov; 6(21):12547-54. PubMed ID: 25179224
[TBL] [Abstract][Full Text] [Related]
55. Lactoferrin coated or conjugated nanomaterials as an active targeting approach in nanomedicine.
Agwa MM; Sabra S
Int J Biol Macromol; 2021 Jan; 167():1527-1543. PubMed ID: 33212102
[TBL] [Abstract][Full Text] [Related]
56. The battle of lipid-based nanocarriers against blood-brain barrier: a critical review.
Abla KK; Mehanna MM
J Drug Target; 2023 Sep; 31(8):832-857. PubMed ID: 37577919
[TBL] [Abstract][Full Text] [Related]
57. Overcoming the Blood-Brain Barrier: The Role of Nanomaterials in Treating Neurological Diseases.
Furtado D; Björnmalm M; Ayton S; Bush AI; Kempe K; Caruso F
Adv Mater; 2018 Nov; 30(46):e1801362. PubMed ID: 30066406
[TBL] [Abstract][Full Text] [Related]
58. Influence of Surface Ligand Density and Particle Size on the Penetration of the Blood-Brain Barrier by Porous Silicon Nanoparticles.
Zhang W; Zhu D; Tong Z; Peng B; Cheng X; Esser L; Voelcker NH
Pharmaceutics; 2023 Sep; 15(9):. PubMed ID: 37765240
[TBL] [Abstract][Full Text] [Related]
59. PLGA nanoparticles prepared by nano-emulsion templating using low-energy methods as efficient nanocarriers for drug delivery across the blood-brain barrier.
Fornaguera C; Dols-Perez A; Calderó G; García-Celma MJ; Camarasa J; Solans C
J Control Release; 2015 Aug; 211():134-43. PubMed ID: 26057857
[TBL] [Abstract][Full Text] [Related]
60. Potential Use of Nanomedicine for Drug Delivery Across the Blood-Brain Barrier in Healthy and Diseased Brain.
Ruozi B; Belletti D; Pederzoli F; Forni F; Vandelli MA; Tosi G
CNS Neurol Disord Drug Targets; 2016; 15(9):1079-1091. PubMed ID: 27633786
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
